Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe Covid-19 Infection

NCT06490744 | Recruiting

• 1 other identifier: 9058
• Study Type: observational
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

The SARS-Cov-2 infection pandemic has caused a large number of acute respiratory failures and deaths across the world. Certain factors have been identified as associated with a higher risk of developing a severe form and dying. Immunosuppression has been identified as a risk factor for progressing to a severe form. Lung transplant patients were particularly vulnerable during this period, with a high frequency of respiratory compromise, sometimes progressing towards acute respiratory distress syndrome and, at a later stage, towards fibrotic forms. The impact of the infection on the immunological status of the patient and on the tolerance of the transplant have been little studied. The various treatments implemented during the pandemic have rapidly evolved (immunotherapy, vaccination, convalescent plasma transfusion, etc.) which may have modulated this risk. The evolution of respiratory function may be linked to the respiratory infection itself, or to the severity of respiratory damage during the infection. It is therefore relevant to compare patients with a moderate form of COVID-19 (non-intubated patients) to patients with severe forms, requiring invasive ventilation in intensive care. The evolution of respiratory function after infection has not yet been studied.

Conditions

COVID-19 Respiratory Infection

Keywords

Covid-19; COVID-19 Pneumonia; COVID-19 Respiratory Infection; SARS-Cov-2

Outcome Measures

Primary Outcomes (1)

• Retrospective description of the evolution of respiratory function in lung transplant recipients after moderate to severe Covid-19.

  This retrospective study concerns lung transplant patients who had a Covid-19 infection and were treated at the Strasbourg University Hospital during the period from March 1, 2020 to December 31, 2022.

  Files analyzed retrospectively cover the period from March 1, 2020 to December 31, 2022.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult lung transplant patients who had a Covid-19 infection and were treated at the Strasbourg University Hospital during the period from March 1, 2020 to December 31, 2022.

You may qualify if:

• Adult patient
• Lung transplant patient (monopulmonary or bipulmonary)
• Covid diagnosed by RT-PCR between March 1, 2020 and December 31, 2022
• Hospitalization at the University Hospitals of Strasbourg for COVID-19
• Patient followed in the context of their lung transplant at the University Hospitals of Strasbourg
• Absence of written opposition in the subject's medical file to the reuse of their data for scientific research purposes.

You may not qualify if:

• Subject having expressed his opposition to the reuse of his data for scientific research purposes.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service d'Anesthésie Réanimation - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Charles Ambroise TACQUARD, MD

CONTACT

33 3 69 55 16 08; charlesambroise.tacquard@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2024
• First Posted: July 8, 2024
• Study Start: September 4, 2023
• Primary Completion: December 1, 2024
• Study Completion: December 31, 2024
• Last Updated: July 8, 2024

Record last verified: 2024-07

Locations

FR (1)